chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Per pt., started to experience extreme itchiness and tachycardia around 8 PM. No other changes to diet or routine besides Influenza vaccine and TB test administered a couple of hours earlier. Pt. had to take a Benadryl around 8:15 PM d/t uncomfortable feeling of itchiness. Pt. called employee health nurse to report reaction on 10/2 @ 9:50 AM. Informed pt. that employee health nurse would be making a VAERS report in which she verbalized understanding. Pt. states that she does have seasonal allergies, and does take Zyrtec for tx. Pt. continues to report some itchiness this morning, but somewhat better than last night. No c/o of SOB, throat closure, etc. Informed pt. to consult PCP in regards to reaction to Influenza vaccine, and to go to ER if she starts experiencing s/s of anaphylaxis reaction in which she verbalized understanding. At this time, pt. states that she feels like she does not need to see her PCP unless s/s worsen, and will inform PCP about Influenza vaccine on scheduled appt. on 10/13.
Myalgia, tingling sensation Narrative: sore arm for 3 days. on 3rd day had tingling in the arm
pt received 3rd dose of covid 19 vaccine.  Pt lost consciousness in chair and was placed on floor by 2 corpsmen.  Feet were elevated.  Pt woke up about 10 seconds later, A&O x4.  Pt stated this has happened before with venipuncture but never a vaccine.  VSS.  RRT arrived and transported patient to ED in stable condition.
Dehydration; Tired; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), DEHYDRATION (Dehydration) and FATIGUE (Tired) in a 94-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037C21A and 044B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced DIARRHOEA (Diarrhea). On an unknown date, the patient experienced DEHYDRATION (Dehydration) and FATIGUE (Tired). On 10-Jun-2021, DIARRHOEA (Diarrhea) had resolved. At the time of the report, DEHYDRATION (Dehydration) and FATIGUE (Tired) had resolved.            Concomitant medications use was not provided. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jul-2021: Follow up was received which contains outcome of all events. Event Dehydration was added.
No adverse event; Patient received the bivalent booster as their first dose/she was supposed to get the primary series but got the booster.; This spontaneous case was reported by an other health care professional and describes the occurrence of INCORRECT DOSE ADMINISTERED (Patient received the bivalent booster as their first dose/she was supposed to get the primary series but got the booster.) and NO ADVERSE EVENT (No adverse event) in a 55-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7145B) for COVID-19 vaccination.     It was unknown if the patient had allergies to medications, food and other products. The patient had not COVID + test or diagnosis. The patient had no acute and chronic illnesses at the time of vaccination. It was unknown if the patient had received other vaccines given within 1 month prior to Moderna COVID-19 vaccine.     On 19-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .5 milliliter. On 19-Sep-2022, the patient experienced INCORRECT DOSE ADMINISTERED (Patient received the bivalent booster as their first dose/she was supposed to get the primary series but got the booster.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (Patient received the bivalent booster as their first dose/she was supposed to get the primary series but got the booster.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (Patient received the bivalent booster as their first dose/she was supposed to get the primary series but got the booster.).    It was unknown if patient was taking medication.  The reporter wanted to know if the patient had to restart the vaccination and what happen for the next vaccination.  No treatment medications were reported.
Rash at injection site of flu vaccine-grouped vesicles and area of induration at site. -Rash/vesicles not seen anywhere else on body -appeared 3 days after injection-itchy initially but not now
Within 30 min receiving vaccine, developed diffuse flat red rash on arms - stomach-chest - back - slight itching - no swelling of extremities or resp. difficulty.
Per message from patient: writhing 3 hrs after injection, lower abdominal swelling and inability to urinate, 9 hrs after injection flu-like symptoms in addition to lower abdominal swelling and pain. 72 hrs after injection abdominal swelling subsided and ability to urinate returned, but still in pain and b.m. is loose and of an abnormal color. Pt states he has had 8 tetanus vaccines and is not a typical reaction for him. Patient was traveling and did not see a healthcare provider while he had symptoms, but waited for them to subside. Was mostly concerned of others possibly having this side effect. We have had no other reports of such.
low grade Fever; Aches; Fatigue; This case was reported by a consumer and described the occurrence of fever in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included covid-19.   On 19th November 2020, the patient received the 2nd dose of Shingrix (intramuscular). On an unknown date, less than a week after receiving Shingrix, the patient experienced fever, pain and fatigue. On an unknown date, the outcome of the fever, pain and fatigue were unknown.   It was unknown if the reporter considered the fever, pain and fatigue to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and had fatigue, Aches, and low grade Fever.  The patient continues to had the symptoms. The reporter consented to follow up.
On June 12, 2019, at 3:40pm, I attended Clinic for my annual Wellness visit at which time Dr. advised I was due for a pneumonia vaccine.  Due to my age, I agreed (my first vaccine since a child for diphtheria).   At approx. 10:30pm that same evening became aware of a loud, intense high-pitch whistling (ringing) as if electromagnetic waves.  Persisting over road noise and music, and very prevalent around non-natural lighting. The symptoms have been constant.
This case was reported by a consumer via call center representative and described the occurrence of inappropriate age at vaccine administration in a 14-week-old male patient who received BEXSERO. On an unknown date, the patient received the 1st dose of BEXSERO. On an unknown date, unknown after receiving BEXSERO, the patient experienced inappropriate age at vaccination administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown. Additional details were provided as follows: This case was reported by patient's parent. The patient received BEXSERO vaccination at 14 weeks of age, which led to inappropriate age at vaccine administration. The reporter was aware about the minimum time required before receiving the second dose was 1 month but she was asking about the maximum number of months allowable between receiving the first and second BEXSERO dose which would still ensure full immunization.
Intermittent side effects/all side effects; Spells,Close to dizziness; Very uncomfortable/very unpleasant; Rash across back; Cold chills across chest; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Intermittent side effects/all side effects), DIZZINESS (Spells,Close to dizziness), FEELING ABNORMAL (Very uncomfortable/very unpleasant), RASH (Rash across back) and CHILLS (Cold chills across chest) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012l20a) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Intermittent side effects/all side effects), DIZZINESS (Spells,Close to dizziness), FEELING ABNORMAL (Very uncomfortable/very unpleasant), RASH (Rash across back) and CHILLS (Cold chills across chest). At the time of the report, VACCINATION COMPLICATION (Intermittent side effects/all side effects), DIZZINESS (Spells,Close to dizziness), FEELING ABNORMAL (Very uncomfortable/very unpleasant), RASH (Rash across back) and CHILLS (Cold chills across chest) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   Reporter did not allow further contact
Severe pain in his left arm around the injection site; He could not raise his arm above shoulder level without severe pain; Unsteady on his feet, almost fell; Injection site was slightly warm to the touch with a small knot in the area of the injection site; Injection site was slightly warm to the touch with a small knot in the area of the injection site; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (He could not raise his arm above shoulder level without severe pain), BALANCE DISORDER (Unsteady on his feet, almost fell), VACCINATION SITE WARMTH (Injection site was slightly warm to the touch with a small knot in the area of the injection site), VACCINATION SITE MASS (Injection site was slightly warm to the touch with a small knot in the area of the injection site) and VACCINATION SITE PAIN (Severe pain in his left arm around the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 mg. On 15-Dec-2021, the patient experienced VACCINATION SITE PAIN (Severe pain in his left arm around the injection site). In December 2021, the patient experienced VACCINATION SITE MOVEMENT IMPAIRMENT (He could not raise his arm above shoulder level without severe pain), BALANCE DISORDER (Unsteady on his feet, almost fell), VACCINATION SITE WARMTH (Injection site was slightly warm to the touch with a small knot in the area of the injection site) and VACCINATION SITE MASS (Injection site was slightly warm to the touch with a small knot in the area of the injection site). The patient was treated with KETOROLAC TROMETHAMINE (TORADOL) at a dose of 1 ml; DEXAMETHASONE at a dose of 1 ml and DICLOFENAC POTASSIUM (ZIPSOR) at a dose of 25 mg four times per day. At the time of the report, VACCINATION SITE MOVEMENT IMPAIRMENT (He could not raise his arm above shoulder level without severe pain), BALANCE DISORDER (Unsteady on his feet, almost fell), VACCINATION SITE WARMTH (Injection site was slightly warm to the touch with a small knot in the area of the injection site) and VACCINATION SITE MASS (Injection site was slightly warm to the touch with a small knot in the area of the injection site) outcome was unknown and VACCINATION SITE PAIN (Severe pain in his left arm around the injection site) was resolving.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.  It was reported that all vital signs of patient were within normal limits.  Patient did not take any OTC, Tylenol or ibuprofen to relieve pain.  Patient reported that he was also given a work excuse for 14-Dec-2021 and to return to work on 17-Dec-2021 at 12 noon.  Patient reported residual effects, soreness in left deltoid.   This case was linked to MOD-2021-385970 (Patient Link).
Day 1 & 2: pain at injection site, fatigue, body aches. Symptoms resolved. Day 7: swelling and itchy at injection site, body aches. Injection site warm to touch. Days 10-12 rash near injection site and itchy small beginnings of skin irritation on several other areas of body.
Pt passed out - pt feel off exam table hit head on wall. She was observed and then sent for a CT of the head which was normal.
Pt c/o having 'weird feeling/not feeling good' and increase heart rate about 7-8 minutes after receiving vaccine. Pt denied any shortness of breath at the time, no swelling of face, BBS clear and equal with equal rise and fall of the chest wall, alert and oriented X 4, able to speak in complete sentences. Progressed to report 'lips feeling like they are swelling approximately 18 minutes after the vaccine was administered. 911 was activated. Epinephrine 0.3 mg IM via epi autoinjector was administered to left thigh. Pt still c/o feeling that her lips were swelling 8 minutes after first dose of Epinephrine; therefore, another dose of 0.3 mg Epinephrine IM via epi autoinjector was administered to left thigh. Diphenhydramine 25 mg IV was administered 2 minutes after second dose of Epinephrine. IV fluids administered as well, while awaiting arrive of EMS. EMS arrived on scene approximately 30 minutes after called. Blood glucose was 120 mg/dl approximately 25 minutes after vaccine administration. Pt report feeling better after the 2nd dose of Epinephrine and Diphendydramine and 500 ml of Normal saline IV. Pt was transported via EMS to the ER for further evaluation and treatment.
Patient reported that at 9:00pm 01/20/2021 she noted body aches, headaches, loose stools and she felt as if she was in a fog
had mild symptoms after 2nd shot and was under the weather for a few days; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (had mild symptoms after 2nd shot and was under the weather for a few days) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010A21A and 015L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced MALAISE (had mild symptoms after 2nd shot and was under the weather for a few days). On 07-Mar-2021, MALAISE (had mild symptoms after 2nd shot and was under the weather for a few days) had resolved.            No concomitant medication  were reported. No Treatment information was provided. This case concerns a 68 year old female with no medical history reported, who experienced non-serious , unexpected event of malaise , which occurred on the same day after vaccination with the 2nd dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine ) . The re-challenge for this case is negative since in the SD report during the 3rd dose this event was not reported to recur. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report   This case was linked to MOD-2021-402762 (Patient Link).; Sender's Comments: This case concerns a 68 year old female with no medical history reported, who experienced non-serious , unexpected event of malaise , which occurred on the same day after vaccination with the 2nd dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine ) . The re-challenge for this case is negative since in the report during the 3rd dose this event was not reported to recur. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report
Swelling at injection site - first day then went away, reappeared 7 days later with joint pain, itchy injection site
After several days I deveoped hearing loss and Ringing of both ears. The ring has contined since then. No remedy
Prickly feeling in left arm by brachial artery and also in right lower leg, outer calf muscle. Very sore left arm.
No adverse event reporting a med error. Needed 6 month set of shots and intended to give Pentacel but gave Pediarix and Engerix B. Child ended up getting 2 doses Hep B and no HIB. Error discovered after they left. PC to mother who said she will call and reschedule the HIB later.
Doses administered past 30 day beyond use date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses administered past 30 day beyond use date) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses administered past 30 day beyond use date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses administered past 30 day beyond use date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Date the vial was initially stored in the refrigerator was unknown. The vial did not undergo any temperature excursions. Vaccine manufacture date of expiry reported was 24-Oct-2021. No treatment details were reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Follow-up received contains no new information.
extreme dry mouth; Feeling cold; Fever; painful arm at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of DRY MOUTH (extreme dry mouth), FEELING COLD (Feeling cold), PYREXIA (Fever) and VACCINATION SITE PAIN (painful arm at the injection site) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021, the patient experienced FEELING COLD (Feeling cold), PYREXIA (Fever) and VACCINATION SITE PAIN (painful arm at the injection site). On an unknown date, the patient experienced DRY MOUTH (extreme dry mouth). On 22-Apr-2021, FEELING COLD (Feeling cold) had resolved. On 23-Apr-2021, PYREXIA (Fever) and VACCINATION SITE PAIN (painful arm at the injection site) had resolved. At the time of the report, DRY MOUTH (extreme dry mouth) had not resolved.            No relevant concomitant medications were reported.   Treatment information was not provided.   This case was linked to MOD-2021-077832 (Patient Link).
Numbness, tingling starting at vaccine admin site and migrating down the left leg and up to left side of my face.
Rash and itchiness extremities and trunk, labs done patient has low platelets/low WBC/lymphopenia, patient states had second dose yesterday 4.9.2021. Treatment plan 25mg IM Benadryl given, 60 mg prednisone given, Atarax 25mg prescribed, Medrol dose pack prescribed, advised to return to clinic tomorrow for repeat CBC and worsening symptoms to go to emergency room.
Immense bruising upper arm. Excruciating shoulder pain - ongoing. Inflamed shoulder joint. Partial tear roto cuff. Shot given high and in back of arm.
Neck pain/tenderness, Shoulder tenderness moving to right side, lymphadenopathy
Pt vaxed 23NOV90 & on 26NOV90 devel a cough which worsened during next wk; fever, myalgia, malaise, & weakness in lower extremities;Polymyalgia rheumatica & temporal arteritis were poss dx; 28JAN91 biopsy pos for arteritis; paresthesias;
This patient reportedly received his COVID vaccination at the hospital on 6/2/2021. The following morning, he was found lying on the bathroom floor. His brother checked on him throughout the day, and the following day (6/4/2021) he was found in the same place but unresponsive. An autopsy examination was performed, and the cause of death was determined to be hypertensive and atherosclerotic cardiovascular disease. No definitive direct link could be made between the vaccine and death during the autopsy examination, but it was decided to report the death. I have no further details of the vaccination.
The unspecified patient received a dose of PNEUMOVAX 23 on an unspecified date. The patient died, on an unspecified date a few years later.; Pneumococcal infection; This spontaneous report was received from a physician via a company representative concerning to a female patient in her 70's. The patient's concurrent conditions included diabetes mellitus. The patient's medical history, allergies, and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with an unspecified dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) for prophylaxis (strength, dose, route of administration, lot # and expiration date were not provided).  The reporter indicated that on an unknown date (reported as "a few years later" after the vaccination), the patient was hospitalized, and she had may been experienced a pneumococcal infection. On an unknown date, she died from an unknown cause of death, at an unspecified hospital. It was also unknown if treatment was given fir the adverse events, if laboratory diagnostics or studies were performed or if the patient sought medical attention.  The causality assessment between the events pneumococcal infection and the patient's death and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not provided.  Upon internal review, the pneumococcal infection was considered to be a medically significant event.; Reported Cause(s) of Death: Unknown cause of death
pt recv vax 7APR97 & on 11APR97 had temp 103 & swelling on lt jaw line from ear to nearly mid face line;MD uncertain whether from mumps component of vax or infect in gland given ATB;swelling  reduced 17APR97;
couldn't get warm/had chills; felt tired; More than 35 days after the first dose without receiving the second dose; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (couldn't get warm/had chills), FATIGUE (felt tired) and PRODUCT DOSE OMISSION ISSUE (More than 35 days after the first dose without receiving the second dose) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039C21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included AMLODIPINE and LISINOPRIL for an unknown indication.    On 19-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHILLS (couldn't get warm/had chills), FATIGUE (felt tired) and PRODUCT DOSE OMISSION ISSUE (More than 35 days after the first dose without receiving the second dose). At the time of the report, CHILLS (couldn't get warm/had chills) and FATIGUE (felt tired) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (More than 35 days after the first dose without receiving the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.  Patient missed appointment for the second dose on 17-jul-2021.